Research analysts at Instinet assumed coverage on shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) in a report issued on Tuesday. The brokerage set a “buy” rating and a $43.00 price target on the biopharmaceutical company’s stock. Instinet’s price target would suggest a potential upside of 156.72% from the company’s current price.
Several other equities analysts also recently commented on the stock. Nomura began coverage on shares of Sucampo Pharmaceuticals in a report on Monday. They issued a “buy” rating and a $43.00 price objective on the stock. BidaskClub upgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 12th. Mizuho upped their price target on shares of Sucampo Pharmaceuticals from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, December 8th. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, December 7th. Finally, Maxim Group set a $23.00 price target on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, December 7th. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $21.00.
Sucampo Pharmaceuticals (NASDAQ SCMP) opened at $16.75 on Tuesday. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $17.70. The company has a market cap of $792.81, a price-to-earnings ratio of 11.64, a price-to-earnings-growth ratio of 5.06 and a beta of 1.47. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.
In related news, insider Peter A. Kiener sold 50,000 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $16.50, for a total value of $825,000.00. Following the transaction, the insider now directly owns 52,023 shares in the company, valued at $858,379.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.13% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. HPM Partners LLC bought a new stake in Sucampo Pharmaceuticals during the second quarter worth about $1,307,000. Trexquant Investment LP purchased a new stake in Sucampo Pharmaceuticals in the 3rd quarter worth about $122,000. Nine Chapters Capital Management LLC purchased a new stake in Sucampo Pharmaceuticals in the 3rd quarter worth about $127,000. JPMorgan Chase & Co. purchased a new stake in Sucampo Pharmaceuticals in the 2nd quarter worth about $117,000. Finally, Aperio Group LLC purchased a new stake in Sucampo Pharmaceuticals in the 3rd quarter worth about $137,000. 65.29% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Sucampo Pharmaceuticals (SCMP) Now Covered by Instinet” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2017/12/19/sucampo-pharmaceuticals-scmp-now-covered-by-instinet.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.